Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Long-Term Investments: 2016-2025

Historic Long-Term Investments for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $380,000.

  • UroGen Pharma's Long-Term Investments fell 91.81% to $380,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $380,000, marking a year-over-year decrease of 91.81%. This contributed to the annual value of $5.0 million for FY2024, which is 11.55% up from last year.
  • As of Q3 2025, UroGen Pharma's Long-Term Investments stood at $380,000, which was down 91.80% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Long-Term Investments registered a high of $10.2 million during Q1 2023, and its lowest value of $203,000 during Q2 2024.
  • In the last 3 years, UroGen Pharma's Long-Term Investments had a median value of $4.6 million in 2025 and averaged $4.5 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first slumped by 99.44% in 2021, then skyrocketed by 2,817.94% in 2023.
  • Over the past 5 years, UroGen Pharma's Long-Term Investments (Quarterly) stood at $675,000 in 2021, then plummeted by 66.96% to $223,000 in 2022, then spiked by 1,918.83% to $4.5 million in 2023, then climbed by 11.55% to $5.0 million in 2024, then plummeted by 91.81% to $380,000 in 2025.
  • Its Long-Term Investments was $380,000 in Q3 2025, compared to $4.6 million in Q2 2025 and $4.5 million in Q1 2025.